Sanofi.jpg” alt=”Sanofi” />

Gilead Sciences has announced plans to acquire Nimbus Apollo, a wholly owned subsidiary of Nimbus Therapeutics LLC, and its Acetyl-CoA Carboxylase (ACC) inhibitor programme for $400m.

Nimbus Therapeutics will also receive an additional $800m during development related milestones over time.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The acquisition enables Gilead Sciences to further develop and strengthen its pipeline, and commercialisation of NDI-010976 and other ACC inhibitors.

Sanofi has announced it will sell its 4.76% stake representing approximately 2.85 million shares in Nichi-iko Pharmaceuticals.

The acquisition represents a sale consideration of approximately $63.42m.

“The acquisition represents a sale consideration of approximately $63.42m.”

Cooper Surgical has acquired Genesis Genetics for $60m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition enables CooperSurgical to further develop its invitro fertilisation (IVF) business and extends its reach in genetic testing targeted to improve IVF pregnancy rates and helps in eliminating severe genetic disorders.

Tonghua Golden-Horse Pharma plans to acquire Chengdu Yongkang pharmaceuticals for $63.5m in cash.

The acquisition will enable Tonghua Golden-Horse Pharma to further develop its product strategy of anti tumour, microbial drugs, musculoskeletal system, nervous system drugs.

DanDrit Biotech has announced its intention to buy OncoSynergy, which enable the former to further develop its oncology pipeline.

Upon closing the acquisition, OncoSynergy employees will be integrated into DanDrit and OncoSynergy’s co-founder and CEO Shawn Carbonell will become the chief science officer and Anne Marie Carbonell will take-up the role of chief medical officer.

Image: Sanofi has said it will sell its 4.76% stake: Photo: courtesy: Sanofi de.